Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4552W HIGH $3.87
Volume
453.40 K
Value Traded
263.08 K
Short % Float
8.09%
-2.32%Week
-5.71%1 Month
+15.25%3 Month
+7.03%6 Month
-90.5%5 Year
-90.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
110.40 M
EPS (TTM)
-0.26
P/E Ratio
-
Ent. Value
57.01 M
Total Shares
139.40 M
Float Shares
88.00 M
Insiders
23.76%
Institutions
28.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
RANI Catalyst Timeline
Dated clinical, regulatory and corporate events for Rani Therapeutics Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rani Therapeutics Holdings, Inc.
198Total events
11Upcoming
33Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Other Regulator MilestoneEx-US Regulatory
RaniPill Capsule platform accepted into FDA Emerging Technology Program
▲Other Regulator MilestoneRaniPillEx-US Regulatory
RaniPill Capsule platform accepted into FDA Emerging Technology Program
●R&D DayPresentation
Rani management to participate in Lake Street BIG10 Conference (1x1 meetings)
▲First Patient DosedRT-114Trial
First participants dosed in Phase 1a expansion cohort of RT-114
obesitysource ↗
▲Topline ReadoutRT-114Clinical Data
Positive initial Phase 1a data for RT-114 announced
obesitysource ↗
▲Partnership / LicenseCorporate
Collaboration with PegBio to explore oral delivery of obesity and metabolic disease molecules
obesity and metabolic diseasesource ↗
▲Primary Endpoint MetRT-114Clinical Data
Positive initial Phase 1a data for RT-114: oral bioavailability >150% relative to subcutaneous
healthy volunteerssource ↗
▲Partnership / LicenseCorporate
Rani Therapeutics and PegBio announce R&D collaboration for oral delivery of obesity candidates
obesity and metabolic diseasesource ↗
▲Primary Endpoint MetRT-114Clinical Data
Positive initial Phase 1a data: oral bioavailability >150% relative to subcutaneous
healthy volunteerssource ↗
▲Partnership / LicenseCorporate
Collaboration with PegBio to explore oral delivery of obesity and metabolic disease molecules
obesity and metabolic diseasesource ↗
▼Equity OfferingCorporate
Pricing of $20.0 million registered direct offering of Class A common stock and pre-funded warrants
◆Oral PresentationPresentation
Rani Therapeutics management to present at H.C. Wainwright Annual BioConnect Investor Conference
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results release and business update
▲Partnership / LicenseCorporate
Up to $1.085 billion collaboration with Chugai Pharmaceutical Co.
●Preclinical PoCsemaglutidePreclinical
Preclinical data demonstrating successful oral delivery of semaglutide via RaniPill
●Preclinical PoCRT-114Preclinical
Preclinical data demonstrating bioequivalence of RT-114 (PG-102) delivered orally via RaniPill to subcutaneous administration
●Oral PresentationPresentation
Conference call to discuss results and provide business update
▲Trial InitiationRT-114Trial
Initiation of Phase 1 study of RT-114 (RaniPill containing PG-102) for obesity
obesitysource ↗
◆Oral PresentationPresentation
Rani Therapeutics to participate in Evercore Healthcare Conference
▲Trial InitiationRT-114Trial
Initiated Phase 1 Study of RT-114 RaniPill for obesity in collaboration with ProGen
obesitysource ↗
◆Poster PresentationRT-116Presentation
Poster presentation of preclinical data on oral semaglutide (RT-116) at ObesityWeek 2025
obesitysource ↗
▲Partnership / LicenseCorporate
Collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics
◆Management ChangeCorporate
Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors
●Debt Royalty FinancingCorporate
Avenue Venture Opportunities Fund converted $6M debt into equity
▲Partnership / LicenseCorporate
Collaboration and License Agreement with Chugai for up to 6 drug targets
rare disease and immunologic diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How RANI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-06 | Oral Semaglutide (RT-116) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$8M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 67%
Micro Cap(rank 441 of 658)
Percentile Rank
Rani Therapeutics Holdings, Inc. faces pipeline headwinds (31/100), with $291M risk-adjusted pipeline value, led by RT-111 in Healthy Volunteers (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RT-111 Small moleculeCompletedNCT05890118 | Healthy Volunteers | Phase 1 | COMPLETED | 55 | Nov 1, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every RANI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RT-114 | obesity | Phase 1 | 2024-10-17 | weight loss transenteric: 9.7 ± 2.5 %; weight loss SC: 6.9 ± 2.1 %; relative bioavailability: 80%Read More | Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin TriagonistRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| IMRAN MIR ADirector, 10% Owner | Buy | 36,000 2,119,334 held | $0.69 | 07/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RANI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 0.6 % | 7.88 M | 10.37 M | 21.99% ( 1.87 M) |
RANI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RANI ranks across every disease it competes in
Competitive Position is a premium feature
See how RANI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRANI News
RANI▼ -2.5%today
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Rani Therapeutics has announced its acceptance into the FDA's Emerging Technology Program for its RaniPill platform. This program allows for early engagement with the FDA, facilitating discussions on technical and regulatory aspects of the technology. The CEO expressed confidence in the platform's potential to replace injectable biologics with oral therapies, supported by partnerships in rare diseases and immunology.
Read more →RANIRani Therapeutics to Participate in Upcoming September Conferences
Rani Therapeutics Holdings, Inc. will participate in two upcoming September conferences, enhancing its visibility in the biotherapeutics sector. The company will engage in 1x1 meetings at the Best Ideas Growth Conference and host a fireside chat at the H.C. Wainwright Global Investment Conference. These events are crucial for discussing Rani's innovative oral delivery technologies.
Read more →RANIRani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Rani Therapeutics reported its second quarter 2026 financial results, highlighting significant advancements in its RT-114 program, including positive initial Phase 1a data. The company also completed a $20 million direct offering and expanded its obesity pipeline through a collaboration with PegBio. Despite a net loss of $8.4 million, Rani's cash position remains strong, expected to fund operations through 2027.
Read more →RANIRani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Rani Therapeutics Holdings, Inc. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference. This event highlights the company's focus on oral delivery of biologics and provides an opportunity for management to engage with investors and stakeholders. The participation reflects Rani's commitment to advancing its clinical-stage biotherapeutics.
Read more →RANIRani Therapeutics Appoints Michelle Gilson to Board of Directors
Rani Therapeutics has appointed Michelle Gilson to its Board of Directors. Gilson, the former Chief Financial Officer of Arcellx, brings significant expertise in capital markets and biotech financial leadership. This appointment is expected to bolster the company's strategic direction as it focuses on the oral delivery of biologics.
Read more →RANIRani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rani Therapeutics has granted a stock option for 2 million shares to Nicholas Maestas, the new CFO, as an inducement for his employment. The option, approved by the Compensation Committee, has an exercise price equal to the closing stock price on the grant date and vests over four years. This move aligns with Nasdaq regulations and supports Rani's focus on oral drug delivery technologies.
Read more →RANIRani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
Rani Therapeutics has announced positive initial results from its Phase 1a study of RT-114, an oral formulation of PG-102 for obesity treatment. The study showed that RT-114 achieved systemic exposure exceeding that of a matched subcutaneous dose, with a favorable safety profile. The company plans to expand the study to better understand the pharmacokinetics before moving to Phase 1b.
Read more →RANIRani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
Rani Therapeutics has announced a collaboration with PegBio to develop oral delivery systems for PegBio's obesity and metabolic disease candidates using the RaniPill® platform. This partnership aims to enhance Rani's existing obesity pipeline by adding multiple new candidates with diverse mechanisms of action. The collaboration reflects Rani's strategy to broaden its offerings in the obesity market.
Read more →RANIRani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Rani Therapeutics has appointed Nicholas Maestas as its new Chief Financial Officer, effective immediately. Maestas brings over a decade of financial leadership experience in the biotechnology sector, previously serving as CFO at Tempest Therapeutics. His appointment follows the departure of Svai Sanford, who led the company through a transitional period. Rani aims to enhance its oral delivery platform for biologics under Maestas' financial stewardship.
Read more →RANI▼ -12.1%on this news
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
Rani Therapeutics Holdings, Inc. has announced a registered direct offering of Class A common stock, aiming to raise approximately $20 million. The offering, priced at $1.07 per share, involves the sale of over 12 million shares and pre-funded warrants. The transaction is expected to close on May 27, 2026, pending customary conditions.
Read more →RANIRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
Rani Therapeutics reported its first quarter 2026 financial results, highlighting advancements in the Phase 1 study of RT-114 for obesity. The company appointed new strategic leaders, including Jesper Høiland and Dr. Sara Kenkare-Mitra, to enhance its pipeline focus. Despite a net loss of $8 million, Rani's financial position remains strong, with sufficient cash to support operations into late 2027.
Read more →RANIRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference 2026
Rani Therapeutics will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. CEO Talat Imran and CFO Svai Sanford will present in a fireside chat format. The conference aims to showcase Rani's advancements in oral delivery technologies for biologics. A live webcast will be available for interested parties.
Read more →RANIRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Rani Therapeutics will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat with CEO Talat Imran and CFO Svai Sanford. The conference aims to showcase Rani's innovative oral delivery technology for biologics. Interested parties can access the live webcast through the company's website.
Read more →RANI▼ -6.1%on this news
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
Rani Therapeutics has appointed Dr. Sara Kenkare-Mitra as a Strategic Advisor to enhance its platform and clinical strategy. With nearly 30 years of experience in drug discovery and development, she will guide the company in prioritizing programs and aligning development plans with regulatory considerations. Her expertise is expected to drive clinical success and long-term value creation for Rani.
Read more →RANI▼ -24.9%on this news
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
Rani Therapeutics reported strong financial results for Q4 and full year 2025, highlighting a $1.085 billion collaboration with Chugai Pharmaceutical. The company also announced successful preclinical data for oral delivery of semaglutide and initiated a Phase 1 study for RT-114, a dual agonist for obesity. Rani's CEO expressed optimism about advancing their RaniPill® platform in 2026.
Read more →RANI▼ -5.3%on this news· ran to -36% by day 3shared move
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Rani Therapeutics has appointed Jesper Høiland as Head of Strategy to enhance its corporate and pipeline strategies. Høiland, who has over 30 years of experience in the pharmaceutical industry, will focus on prioritizing internal programs and exploring new therapeutic opportunities. His expertise is expected to strengthen Rani's strategic partnerships and advance its innovative oral delivery platform.
Read more →RANIRani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Rani Therapeutics will announce its financial results for Q4 and the full year 2025 on March 26, 2026. The company will also provide a business update during a conference call and webcast. The RaniPill® capsule technology aims to replace traditional injection methods with oral dosing, showcasing Rani's commitment to innovation in drug delivery.
Read more →RANIRani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Rani Therapeutics has promoted Alireza Javadi, Ph.D., to Chief Technical Officer. His extensive experience in medical devices and life sciences is expected to enhance Rani's supply chain and manufacturing capabilities. This promotion comes as the company embarks on a Phase 1 study of RT-114 for obesity treatment, marking a pivotal moment in its growth.
Read more →RANIRani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen
Rani Therapeutics has launched a Phase 1 study for RT-114, an orally administered capsule containing the GLP-1/GLP-2 dual agonist, PG-102, aimed at treating obesity. This collaboration with ProGen involves evaluating safety and efficacy parameters that could enhance patient experience compared to traditional injection methods. Recent data showcases PG-102's potential in glucose management and weight-loss, reinforcing its promise as an innovative metabolic therapy. Both companies will jointly develop RT-114 while sharing costs and profits from commercialization.
Read more →About Rani Therapeutics Holdings, Inc.
Headquarters2051 RINGWOOD AVENUE, SAN JOSE, CA, 95131
BIOPHARMAWATCH ELITE PLUS
Trade the next RANI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime